Pediatric Long-Term Follow-up and Rollover Study
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
55 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
- Novartis Investigative Site
Darlinghurst, New South Wales, Australia
- Novartis Investigative Site
Parkville, Victoria, Australia
- Novartis Investigative Site
Brussels, Belgium
- Novartis Investigative Site
Barretos, São Paulo, Brazil
- Novartis Investigative Site
São Paulo, São Paulo, Brazil
- Novartis Investigative Site
São Paulo, São Paulo, Brazil
- Novartis Investigative Site
Vancouver, British Columbia, Canada
- Novartis Investigative Site
Toronto, Ontario, Canada
- Novartis Investigative Site
Montreal, Quebec, Canada
- Novartis Investigative Site
Brno, Czechia
- Novartis Investigative Site
Prague, Czechia
- Novartis Investigative Site
Copenhagen, Denmark
- Novartis Investigative Site
Tampere, Finland
- Novartis Investigative Site
Rennes, Brittany Region, France
- Novartis Investigative Site
Brest, France
- Novartis Investigative Site
Marseille, France
- Novartis Investigative Site
Paris, France
- Novartis Investigative Site
Rennes, France
- Novartis Investigative Site
Vandœuvre-lès-Nancy, France
- Novartis Investigative Site
Villejuif, France
- Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
- Novartis Investigative Site
Augsburg, Germany
- Novartis Investigative Site
Berlin, Germany
- Novartis Investigative Site
Essen, Germany
- Novartis Investigative Site
Hamburg, Germany
- Novartis Investigative Site
Petah Tikva, Israel
- Novartis Investigative Site
Florence, FI, Italy
- Novartis Investigative Site
Genova, GE, Italy
- Novartis Investigative Site
Milan, MI, Italy
- Novartis Investigative Site
Roma, RM, Italy
- Novartis Investigative Site
Torino, TO, Italy
- Novartis Investigative Site
Setagaya-ku, Tokyo, Japan
- Novartis Investigative Site
Osaka, Japan
- Novartis Investigative Site
Utrecht, Netherlands
- Novartis Investigative Site
Moscow, Russia
- Novartis Investigative Site
Madrid, Spain
- Novartis Investigative Site
Valencia, Spain
- Novartis Investigative Site
Stockholm, Sweden
- Novartis Investigative Site
Sutton, Surrey, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Nov 2019
- Primary completion
- 5 Nov 2026
- Completion
- 5 Nov 2026
- Last update posted
- 7 Jul 2026
- Registered enrollment
- 163
- Registry id
- NCT03975829
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.